ABCA1 p.Thr1512Met

[switch to full view]
Comments [show]
Publications
PMID: 21575609 [PubMed] Sorrenson B et al: "An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutations."
No. Sentence Comment
2 Following the finding of three different ABCA1 mutations, p.C978fsX988, p.T1512M and p.N1800H in a subject with hypoalphalipoproteinemia, we aimed to establish whether the p.C978fsX988 truncation exerted a dominant negative effect on the full-length ABCA1 alleles within family members as has been reported for other ABCA1 truncations.
X
ABCA1 p.Thr1512Met 21575609:2:74
status: NEW
Login to comment

29 In this study, we characterised a pedigree with three different ABCA1 mutations; p.N1800H, p.C978fsX988 and p.T1512M.
X
ABCA1 p.Thr1512Met 21575609:29:110
status: NEW
Login to comment

30 The p.N1800H is a common ABCA1 mutation known to impair function [1,6,11,12].
X
ABCA1 p.Thr1512Met 21575609:30:110
status: NEW
Login to comment

31 The p.C978fsX988 and p.T1512M mutations were recently reported but were not characterised with respect to segregation, expression or function in the case of the p.C978fsX988 mutation [13].
X
ABCA1 p.Thr1512Met 21575609:31:23
status: NEW
Login to comment

32 Here we show that the p.C978fsX988 and p.T1512M mutations are on the same allele and that the p.C978fsX988 protein is dysfunctional.
X
ABCA1 p.Thr1512Met 21575609:32:23
status: NEW
X
ABCA1 p.Thr1512Met 21575609:32:41
status: NEW
Login to comment

33 This situation gave us the unique opportunity to test the effect of a short ABCA1 truncation on the expression and function of both the wildtype and the p.N1800H ABCA1 alleles.
X
ABCA1 p.Thr1512Met 21575609:33:41
status: NEW
Login to comment

72 The T1512 primer was used to amplify the wildtype and p.N1800H alleles and the M1512 primer to amplify the p.C978fsX988/p.T1512M allele.
X
ABCA1 p.Thr1512Met 21575609:72:122
status: NEW
Login to comment

84 Sequencing showed the proband (I:1) was heterozygote for three mutations; p.C978fsX988 (c.2934delT), p.T1512M (c.4535C > T) and p.N1800H (c.5398A > C).
X
ABCA1 p.Thr1512Met 21575609:84:103
status: NEW
Login to comment

87 The daughter (II:2) was heterozygous for the N1800H mutation and the son (II:1) heterozygous for the p.C978fsX988 and p.T1512M mutations making it apparent that the p.C978fsX988 and p.T1512M mutations were on the same allele.
X
ABCA1 p.Thr1512Met 21575609:87:120
status: NEW
X
ABCA1 p.Thr1512Met 21575609:87:184
status: NEW
Login to comment

109 The proband, a compound heterozygote for the p.C978fsX988, p.T1512M and p.N1800H mutations, exhibited a low HDL-C level (0.23 mmol/L) but showed no signs of Tangier disease.
X
ABCA1 p.Thr1512Met 21575609:109:61
status: NEW
Login to comment

110 Segregation of alleles within the family showed the p.C978fsX988 and p.T1512M mutations to be on the same allele making the p.T1512M mutation effectively redundant.
X
ABCA1 p.Thr1512Met 21575609:110:61
status: NEW
X
ABCA1 p.Thr1512Met 21575609:110:71
status: NEW
X
ABCA1 p.Thr1512Met 21575609:110:126
status: NEW
Login to comment

111 As few studies have characterised the effect of truncated ABCA1 alleles [9,10,17], this family gave us a unique opportunity to test the effect of a short truncated allele on both the full-length wildtype and p.N1800H alleles.
X
ABCA1 p.Thr1512Met 21575609:111:71
status: NEW
X
ABCA1 p.Thr1512Met 21575609:111:126
status: NEW
Login to comment

121 The p.C978fsX988/ p.T1512M and p.N1800H alleles are represented by grey and black shading respectively.
X
ABCA1 p.Thr1512Met 21575609:121:20
status: NEW
Login to comment

73 The T1512 primer was used to amplify the wild-type and p.N1800H alleles and the M1512 primer to amplify the p.C978fsX988/p.T1512M allele.
X
ABCA1 p.Thr1512Met 21575609:73:123
status: NEW
Login to comment

85 Sequencing showed the proband (I:1) was heterozygote for three mutations; p.C978fsX988 (c.2934delT), p.T1512M (c.4535C > T) and p.N1800H (c.5398A > C).
X
ABCA1 p.Thr1512Met 21575609:85:103
status: NEW
Login to comment

88 The daughter (II:2) was heterozygous for the N1800H mutation and the son (II:1) heterozygous for the p.C978fsX988 and p.T1512M mutations making it apparent that the p.C978fsX988 and p.T1512M mutations were on the same allele.
X
ABCA1 p.Thr1512Met 21575609:88:120
status: NEW
X
ABCA1 p.Thr1512Met 21575609:88:184
status: NEW
Login to comment

122 The p.C978fsX988/ p.T1512M and p.N1800H alleles are represented by grey and black shading respectively.
X
ABCA1 p.Thr1512Met 21575609:122:20
status: NEW
Login to comment

PMID: 20880529 [PubMed] Candini C et al: "Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol."
No. Sentence Comment
61 Eight novel missense variations [c.299C > G (p.S100C), c.1724A > G (p.D575G), c.1779C > G (p.F593L), c.3167T > C (p.L1056P), c.3757G > A (p.E1253K), c.4535C > T (p.T1512M), c.5573T > C (p.V1858A), c.5821T > C (p.C1941R)] were introduced into this chimeric construct by site-directed mutagenesis using Stratagene QuikChange XL site-directed mutagenesis kit according to manufacturer`s instructions (La Jolla, CA, USA).
X
ABCA1 p.Thr1512Met 20880529:61:164
status: NEW
Login to comment

76 Patients (gender, age) Amino acida (nucleotidea ) change TC TG LDL-c HDL-c Clinical manifestations of TD CVD Other relevant clinical data Homozygotes Patient 1 (female, 42) p.L1056P (c.3167T > C) 2.4 0.9 1.99 <0.10 Absent CAD Thrombocytopenia Patient 2 (male, 40) p.Wl747X (c.5240G > A) 1.76 1.93 0.52 0.1-0.3 Neuropathy, splenomegaly, thrombocytopenia Mild stenosis (20-30%) of coronary arteries None Patient 3 (male, 55) p.F593L (c.1779C > G) 4.4 1.4 3.6 <0.10 Absent CAD None p.E1253K (c.3757G > A) Compound heterozygotes Patient 4 (female, 63) p.Q1038X (c.3112C > T) 6.68 2.72 5.4 <0.10 Absent None None p.N1800H (c.5398A > C) [32] Patient 5 (female, 28) p.T1512M (c.4535C > T) 4.42 1.83 3.46 0.1 Absent None None p.N1800H (c.5398A > C) [32] p.C978fsX988 (c.2934delT) Patient 6 (female, 17) p.D575G (c.1724A > G) 4.96 2.84 4.35 <0.10 Absent None DM1 p.C1941R(c.5821T > C) Heterozygotes Patient 7 (male, 42) p.S100C (c.299C > G) 8.5 8.7 4.3 0.3 N.A. None None Patient 8 (male, 58) p.E1172D (c.3516G > C) [33] 6.4 2.7 4.1 0.9 N.A. None None Patient 9 (male, 35) p.S1181F (c.3542C > T) [17] 2.9 0.31 1.88 0.88 N.A. None None Patient 10 (male, 48) p.C1477R (c.4429T > C) [13] 2.01 1.4 0.92 0.46 N.A. CAD None Patient 11 (male, 68) p.V1858A (c.5573T > C) 4.9 3.78 2.41 0.75 N.A. CAD None Patient 12 (female, 36) p.N1800H (c.5398A > C) [32] 4.6 1.2 4 <0.10 N.A. None DM2, obesity Patient 13 (male, 67) p.R282X (c.844C > T) [34] 3.2 1.21 2.14 0.51 N.A. None DM2 Patient 14 (female, 42) p.W424X (c.1272G > A) 2.07 1.04 1.39 0.21 N.A. None None Patient 15 (female, 52) N.A. - (IVS11 - 1G > A) 5.51 3.51 3.28 0.56 N.A. None Hypothyroidism, hypertension Patient 16 (female, 54) N.A. - (IVS48 + 2T > C) 3.29 1.92 1.94 0.49 N.A. None DM2, hypertension a Nomenclature based on guidelines of Human Genome Variation Society.
X
ABCA1 p.Thr1512Met 20880529:76:661
status: NEW
Login to comment

89 In ABCA1, we identified 14 novel and 5 known genetic variations in 16 subjects including one frameshift (p.C978fsX988), 2 splice-site (IVS11-1G > C and IVS48 + 2T > C), 4 nonsense (p.R282X, p.W424X, p.Q1038X, p.Wl747X) and 12 missense variations (p.S100C, p.D575G, p.F593L, p.L1056P, p.E1172D, p.S1181F, p.E1253K, p.C1477R, p.T1512M, p.N1800H, p.V1858A, p.C1941R).
X
ABCA1 p.Thr1512Met 20880529:89:326
status: NEW
Login to comment

94 From eight novel missense variations identified in our cohort, one is localized in the first transmembrane domain (p.S100C), two in the first large extracellular loop (p.D575G and p.F593L), two in the first Nuclear Binding Domain (p.L1056P and p.E1253K), one in the second large extracellular loop (p.T1512M), one in the extracellular region, close to the plasma membrane (p.V1858A) and one is localized in the C-terminal domain (p.C1941R).
X
ABCA1 p.Thr1512Met 20880529:94:301
status: NEW
Login to comment

98 Four out of eight mutations were predicted to be probably damaging (p.S100C, p.D575G, p.T1512M, p.C1941R), two as possibly damaging (p.F593L and p.L1056P) and two were described as benign (p.E1253K and p.V1858A) by PolyPhen.
X
ABCA1 p.Thr1512Met 20880529:98:88
status: NEW
Login to comment

110 Fig. 2 shows that the ABCA1-p.S100C, p.D575G, p.F593L, p.L1056P, p.E1253K, p.T1512M, p.C1941R mutant proteins all had a significantly reduced capacity to efflux cholesterol to apo A-I compared to wild-type ABCA1 which is in line with the low HDL cholesterol levels of the individuals in whom the mutations were identified.
X
ABCA1 p.Thr1512Met 20880529:110:77
status: NEW
Login to comment

148 The ABCA1-p.F593L and ABCA1-p.D575G mutations are located in the first large extracellular loop, while ABCA1-p.T1512M is located in the second extracellular loop.
X
ABCA1 p.Thr1512Met 20880529:148:111
status: NEW
Login to comment

PMID: 23087442 [PubMed] Sorrenson B et al: "Functional rescue of mutant ABCA1 proteins by sodium 4-phenylbutyrate."
No. Sentence Comment
16 Nine different ABCA1 mutants (p.A594T, p.I659V, p.R1068H, p.T1512M, p.Y1767D, p.N1800H, p.R2004K, p.A2028V, p.Q2239N) expressed in HEK293 cells, displaying different degrees of mislocalization to the plasma membrane and discrete impacts on cholesterol efflux, were subject to treatment with 4-PBA.
X
ABCA1 p.Thr1512Met 23087442:16:60
status: NEW
Login to comment

53 The Pearson`s correlation coefficient between the GFP and AlexaFluor594 of the ABCA1 mutations were previously identified in low HDL-C subjects and included three uncharacterized mutations, p.I659V, p.R2004K, and p.A2028V (18) and three variants, p.R1068H, p.T1512M, and p.N1800H, known to have reduced localization and cholesterol efflux (19, 20).
X
ABCA1 p.Thr1512Met 23087442:53:259
status: NEW
Login to comment

85 4-PBA rescues mutant ABCA1 localization and improves cholesterol efflux function in transfected HEK293 cells 4-PBA treatment was applied to the six uncharacterized ABCA1 mutants as well as to three mutants that we have previously shown to have reduced cholesterol efflux function, p.R1068H (19), p.T1512M (20), and p.N1800H (20, Fig. 1).
X
ABCA1 p.Thr1512Met 23087442:85:298
status: NEW
Login to comment

109 Upon 4-PBA treatment, efflux function was significantly increased relative to the untreated level for the p.R1068H, p.T1512M, p.Y1767D, p.N1800H, p.R2004K, and p.A2028V mutants (Fig. 3B).
X
ABCA1 p.Thr1512Met 23087442:109:118
status: NEW
Login to comment

112 Treatment with 4-PBA induced a significant increase in colocalization for the p.A594T, p.R1068H, p.T1512M, p.Y1767D, p.N1800H, and p.R2004K mutants. Treatment with 4-PBA did not affect the colocalization of the wild-type ABCA1-GFP protein (supplementary Fig. II).
X
ABCA1 p.Thr1512Met 23087442:112:99
status: NEW
Login to comment

PMID: 24097981 [PubMed] Quazi F et al: "Differential phospholipid substrates and directional transport by ATP-binding cassette proteins ABCA1, ABCA7, and ABCA4 and disease-causing mutants."
No. Sentence Comment
65 Mutations introduced by overlap extension PCR using Pfu AD DNA polymerase in ABCA1 included S100C, W590S, F593L, N935S, T929I, C1477R, T1512M, R2081W, and P2150L.
X
ABCA1 p.Thr1512Met 24097981:65:135
status: NEW
Login to comment

67 ABCA1-MM was constructed to harbor the Walker A-motif lysine-to-methionine mutations K939M/K1952M by the nested PCR method; ABCA4-MM had the corresponding K969M/ K1969M Walker A mutations (37), and ABCA7-MM had the Lipid Transport Activity of ABCA Transporters NOVEMBER 29, 2013ߦVOLUME 288ߦNUMBER 48 JOURNAL OF BIOLOGICAL CHEMISTRY 34415 at SEMMELWEIS UNIV OF MEDICINE on December 3, K847M/K1833M Walker A mutations.
X
ABCA1 p.Thr1512Met 24097981:67:135
status: NEW
Login to comment

208 Expression and Purification of Disease-causing ABCA1 and ABCA4 Mutants-As part of this study, we have generated a number of disease-causing mutations in ABCA1 and ABCA4 to determine their effect on the expression and functional properties of these transporters. We focused our studies on nine missense mutations in ABCA1 known to cause Tangier disease, including three (S100C, W590S, and F593L) in ECD1, two (T929I and N935S) in the NBD1, two (C1477R and T1512M) in ECD2, one (R2081W) in NBD2, and one (P2150L) in the C-terminal segment as shown in Fig. 6A (blue).
X
ABCA1 p.Thr1512Met 24097981:208:455
status: NEW
Login to comment

230 By contrast, the T1512M mutation in ECD2 and P2150L in the C-terminal segment exhibited ATPase activity similar to the WT protein.
X
ABCA1 p.Thr1512Met 24097981:230:17
status: NEW
X
ABCA1 p.Thr1512Met 24097981:230:182
status: NEW
Login to comment

232 ABCA4 variants showed a similar ATPase activity profile as the ABCA1 mutants with the exception of the T1537M mutation of ABCA4, which was significantly lower than the corresponding T1512M mutant in ABCA1.
X
ABCA1 p.Thr1512Met 24097981:232:182
status: NEW
Login to comment

234 As shown in Fig. 8, A and B, the Fl-PC flippase activity of the ABCA1 mutants and the Fl-PE flippase activity of ABCA4 mutants have a similar profile with the ABCA1 variants C1477R, T1512M, and P2150L and corresponding ABCA4 variants C1502R, T1537M, and P2180L showing transport activities ranging from 60 to 80% of the WT protein and the other mutants showing reduced activity in the range of 20-40% of the WT protein.
X
ABCA1 p.Thr1512Met 24097981:234:182
status: NEW
Login to comment

295 The ABCA1/ABCA4 mutants in the ECD1 (S100C/S100P, W590S/ W605S, and F593L/F608L) displayed the lowest activities (20-30% WT), whereas those in the ECD2 (C1477R/C1502R and T1512M/T1537M) and the P2150L/P2180L mutants in the C terminus showed the highest activities (60-100% WT).
X
ABCA1 p.Thr1512Met 24097981:295:171
status: NEW
Login to comment

211 Expression and Purification of Disease-causing ABCA1 and ABCA4 Mutants-As part of this study, we have generated a number of disease-causing mutations in ABCA1 and ABCA4 to determine their effect on the expression and functional properties of these transporters. We focused our studies on nine missense mutations in ABCA1 known to cause Tangier disease, including three (S100C, W590S, and F593L) in ECD1, two (T929I and N935S) in the NBD1, two (C1477R and T1512M) in ECD2, one (R2081W) in NBD2, and one (P2150L) in the C-terminal segment as shown in Fig. 6A (blue).
X
ABCA1 p.Thr1512Met 24097981:211:455
status: NEW
Login to comment

233 By contrast, the T1512M mutation in ECD2 and P2150L in the C-terminal segment exhibited ATPase activity similar to the WT protein.
X
ABCA1 p.Thr1512Met 24097981:233:17
status: NEW
Login to comment

235 ABCA4 variants showed a similar ATPase activity profile as the ABCA1 mutants with the exception of the T1537M mutation of ABCA4, which was significantly lower than the corresponding T1512M mutant in ABCA1.
X
ABCA1 p.Thr1512Met 24097981:235:182
status: NEW
Login to comment

237 As shown in Fig. 8, A and B, the Fl-PC flippase activity of the ABCA1 mutants and the Fl-PE flippase activity of ABCA4 mutants have a similar profile with the ABCA1 variants C1477R, T1512M, and P2150L and corresponding ABCA4 variants C1502R, T1537M, and P2180L showing transport activities ranging from 60 to 80% of the WT protein and the other mutants showing reduced activity in the range of 20-40% of the WT protein.
X
ABCA1 p.Thr1512Met 24097981:237:182
status: NEW
Login to comment

298 The ABCA1/ABCA4 mutants in the ECD1 (S100C/S100P, W590S/ W605S, and F593L/F608L) displayed the lowest activities (20-30% WT), whereas those in the ECD2 (C1477R/C1502R and T1512M/T1537M) and the P2150L/P2180L mutants in the C terminus showed the highest activities (60-100% WT).
X
ABCA1 p.Thr1512Met 24097981:298:171
status: NEW
Login to comment

64 Mutations introduced by overlap extension PCR using Pfu AD DNA polymerase in ABCA1 included S100C, W590S, F593L, N935S, T929I, C1477R, T1512M, R2081W, and P2150L.
X
ABCA1 p.Thr1512Met 24097981:64:135
status: NEW
Login to comment

206 Expression and Purification of Disease-causing ABCA1 and ABCA4 Mutants-As part of this study, we have generated a number of disease-causing mutations in ABCA1 and ABCA4 to determine their effect on the expression and functional properties of these transporters. We focused our studies on nine missense mutations in ABCA1 known to cause Tangier disease, including three (S100C, W590S, and F593L) in ECD1, two (T929I and N935S) in the NBD1, two (C1477R and T1512M) in ECD2, one (R2081W) in NBD2, and one (P2150L) in the C-terminal segment as shown in Fig. 6A (blue).
X
ABCA1 p.Thr1512Met 24097981:206:455
status: NEW
Login to comment

228 By contrast, the T1512M mutation in ECD2 and P2150L in the C-terminal segment exhibited ATPase activity similar to the WT protein.
X
ABCA1 p.Thr1512Met 24097981:228:17
status: NEW
Login to comment

293 The ABCA1/ABCA4 mutants in the ECD1 (S100C/S100P, W590S/ W605S, and F593L/F608L) displayed the lowest activities (2030% WT), whereas those in the ECD2 (C1477R/C1502R and T1512M/T1537M) and the P2150L/P2180L mutants in the C terminus showed the highest activities (60-100% WT).
X
ABCA1 p.Thr1512Met 24097981:293:170
status: NEW
Login to comment